J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More

Daily round-up of news and notes from the 2017 J.P. Morgan Healthcare conference in San Francisco. Regeneron CEO rebuffs Amgen’s patent battle strategy; Teva CEO apologizes for reduced financial guidance; Merck looks for more Keytruda wins, combos; Lilly awaits potentially differentiating Phase III CDK4/6 data; Alkermes readies ALKS 5461 depression submission; Biden discusses cancer moonshot; FDA’s real world evidence views; and UniQure turns a corner.

GoldKeyInPuzzle_1200x675

The legal battle between Amgen Inc. and Sanofi/Regeneron Pharmaceuticals Inc. is intensifying over rival PCSK9 blockers for high cholesterol – and words were exchanged in separate investor presentations at the J.P. Morgan Healthcare conference in San Francisco.

Amgen recently won an injunction blocking sales of Sanofi/Regeneron’s Praluent (alirocumab), which was found to infringe patents for Amgen’s Repatha...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip